Since publication of the original version of this article (1), issues with two cell lines used in the experiments described in Fig. 1B have been reported. The WRO cell line has been found to likely be papillary, not follicular, thyroid cancer cells (2, 3), so the experiments using the WRO cells were repeated using the TT2609-C02 follicular thyroid cancer cell line. In addition, the ARO anaplastic thyroid carcinoma cell line has been reported to be contaminated with the HT-29 colon carcinoma cell line (4), so the experiments using the ARO cells were repeated with the undifferentiated thyroid cancer cell lines HTC-C3, CAL-62, 8505C, 8305C, and BHT-101. The figure and relevant text have been corrected in the latest online PDF version of the article. The authors regret this error.

Another Correction notice (5) was previously published for this article that does not include the correction of Fig. 1B. The publisher regrets this error.

1.
Siragusa
M
,
Zerilli
M
,
Iovino
F
,
Francipane
MG
,
Lombardo
Y
,
Ricci-Vitiani
L
, et al
MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells
.
Cancer Res
2007
;
67
:
5522
30
.
2.
Saiselet
M
,
Floor
S
,
Tarabichi
M
,
Dom
G
,
Hebrant
A
,
van Staveren
WC
, et al
Thyroid cancer cell lines: an overview
.
Front Endocrinol
2012
;
3
:
133
.
3.
Valgode
FGS
,
da Silva
MA
,
Vieira
DP
,
Ribela
M
,
Bartolini
P
,
Okazaki
K
. 
Cytotoxic and genotoxic effects of (131) I and (60) Co in follicular thyroid cancer cell (WRO) with and without recombinant human thyroid-stimulating hormone treatment
.
Environ Mol Mutagen
2017
;
58
:
451
61
.
4.
Zhao
M
,
Sano
D
,
Pickering
CR
,
Jasser
SA
,
Henderson
YC
,
Clayman
GL
, et al
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites
.
Clin Cancer Res
2011
;
17
:
7248
64
.
5.
Correction: MUC1 oncoprotein promotes refractoriness to chemotherapy in thyroid cancer cells
.
Cancer Res
2018
;
78
:
4101
.